SFX by Ex Libris Inc.

Title:	Structures of HIV-1 gp120 Envelope Glycoproteins from Laboratory-Adapted and Primary Isolates
Source:	Structure [0969-2126] Kwong, Peter yr:2001

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Tugarinov, V. "NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding." Structure 8.4 (2000): 385-395.
description	2.	Berkhout, B. "Is there a future for antiviral fusion inhibitors?" Current Opinion in Virology 2.1 (2012): 50-59.
description	3.	Zhang, W. "Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4." Biochemistry 40.6 (2001): 1662-1670.
description	4.	Rizzuto, C D D. "A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding." Science 280.5371 (1998): 1949-53.
description	5.	Cusack, S. "Mutual conformational adaptations in antigen and antibody upon complex formation between an Fab and HIV-1 capsid protein p24." Structure 8.10 (2000): 1069-77.
description	6.	Sharon, M. "Alternative Conformations of HIV-1 V3 Loops Mimic Î² Hairpins in Chemokines, Suggesting a Mechanism for Coreceptor Selectivity." Structure 11.2 (2003): 225-36.
description	7.	Hendrickson, Peter D. "Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody." Nature 393.6686 (1998): 648-59.
description	8.	Jang, Y J J. "Anti-DNA antibodies: aspects of structure and pathogenicity." Cellular and molecular life sciences 60.2 (2003): 309-20.
description	9.	Zhou, N. "Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines." The Journal of biological chemistry (2002): 17476-85.
description	10.	Lundin, A. "Two novel fusion inhibitors of human respiratory syncytial virus." Antiviral research 88.3 (2010): 317-324.
description	11.	De Clercq, E. "Antiretroviral drugs." Current opinion in pharmacology 10.5 (2010): 507-515.
description	12.	Pang, W. "Current peptide HIV type-1 fusion inhibitors." Antiviral chemistry & chemotherapy 20.1 (2009): 1-18.
description	13.	Sanders, Dirk W. "Detailed mechanistic insights into HIV-1 sensitivity to three generations fusion inhibitors." The Journal of biological chemistry 284.39 (2009): 26941-26950.
description	14.	THALI, M. "CHARACTERIZATION OF CONSERVED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 NEUTRALIZATION EPITOPES EXPOSED UPON GP120-CD4 BINDING." Journal of virology 67.7 (1993): 3978-3988.
description	15.	Greenwell, T K K. "Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection." Proceedings of the National Academy of Sciences of the United States of America 91.21 (1994): 9770-4.
description	16.	Prasad, L. "The 2.5 A resolution structure of the jel42 Fab fragment/HPr complex." Journal of molecular biology (1998): 829-45.
description	17.	Tugarinov, V. "Letter to the Editor: Backbone and C-beta assignments of the anti-gp120 antibody Fv fragment complexed with an antigenic peptide." Journal of biomolecular NMR 13.2 (1999): 193-194.
description	18.	Rosen, O. "Induced fit in HIV-neutralizing antibody complexes: Evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization." Biochemistry 44.19 (2005): 7250-7258.
description	19.	Romijn, R A A. "Identification of the collagen-binding site of the von Willebrand factor A3-domain." The Journal of biological chemistry 276.13 (2001): 9985-91.
description	20.	Gaschen, Brian, B. "Diversity Considerations in HIV-1 Vaccine Selection." Science 296.5577 (2002): 2354-2360.